Olympus (TSE:7733) Moat Score: 7/10 (As of Jul. 09, 2026)


TSE:7733 Olympus Corp TSE:7733
80 GF Score
Price 円1,741.00
GF Value 円2,598.22
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Olympus Moat Score?

Olympus TSE:7733 -1.64% 80 Moat Score is 7 as of Jul. 09, 2026. GuruFocus rates TSE:7733 with a GF Score™ of 80/100 and a GF Value™ of 円2,598.22 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 843 Medical Devices & Instruments companies, Olympus ranks better than 98.93% on this metric.

Olympus has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Olympus has Wide Moat: Olympus Corp has a dominant position in medical imaging and endoscopy, supported by strong brand strength, valuable patents, and significant customer loyalty. Its durable cost advantages and innovation capabilities justify an entry-level wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Olympus might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Olympus  (TSE:7733) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Olympus Moat Score Related Terms

TSE:7733 vs ABT, SYK, MDT: Moat Score Comparison

For the Medical Devices subindustry, Olympus's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Olympus Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Olympus's Moat Score distribution charts can be found below:

* The bar in red indicates where Olympus's Moat Score falls into.


TSE:7733
80GF Score
Olympus Corp TSE:7733
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Olympus (TSE:7733) has a Moat Score of 7 as of Jul. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Olympus ranks #9 out of 843 companies in the Medical Devices & Instruments industry, placing it in the top 1.1%.
Is Olympus' Moat Score too high?
Olympus' current Moat Score is 7. Based on the distribution chart, Olympus ranks #9 out of 843 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Olympus has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Olympus' Moat Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Olympus ranks #9 out of 843 companies for Moat Score. This places Olympus in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Olympus's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olympus stock overvalued right now?
Based on GuruFocus' analysis, Olympus (TSE:7733) is currently considered Significantly Undervalued. The stock's GF Value™ is 円2,598.22, compared to a current price of 円1,741.00 — trading 33% below its estimated fair value. The current Moat Score is 7. Olympus' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Olympus (TSE:7733), the current Moat Score is 7 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Olympus (TSE:7733) Overvalued in 2026?

Based on GuruFocus' analysis, Olympus stock appears to be undervalued. The current stock price of 円1,741.00 is trading 33% below its estimated GF Value™ of 円2,598.22. GuruFocus considers Olympus to be Significantly Undervalued.

Key valuation signals for TSE:7733:

  • Moat Score: 7
  • GF Value™: 円2,598.22 vs. price of 円1,741.00 (33% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the TSE:7733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Olympus Business Description

Address 2951 Ishikawacho, Hachioji, JPN, 192-8507
Olympus is a medical-device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.
80GF Score

Get the complete analysis for TSE:7733

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,741.00
Price
円2,598.22
GF Value